This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berry, P. H. Articles by Jensen, R. Search for Related Content PubMed PubMed Citation Articles by Berry, P. H. Articles by Jensen, R.

American Journal of Pathology, Vol 132, 427-443, Copyright © 1988 by American Society for Investigative Pathology

REGULAR ARTICLES

Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

PH Berry, JS MacDonald, AW Alberts, S Molon-Noblot, JS Chen, CY Lo, MD Greenspan, H Allen, G Durand-Cavagna and R Jensen
Department of Safety Assessment, Merck Sharp & Dohme-Chibret, Riom, France.

The cholesterol lowering compound lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (EC 1.1.1.34 HMG CoA reductase), was given in nine separate experiments to normocholesterolemic dogs at rates up to 180 times the maximum therapeutic dose in man (1 mg/kg/day). Mean serum total cholesterol concentrations were reduced as much as 88% below normal. Clinical evidence of neurotoxicity occurred in up to 37% of animals given 180 mg/kg/day lovastatin for 11 or more days, especially in one laboratory where the dosing regime resulted in higher concentrations of plasma drug levels. Dogs receiving 60 mg/kg/day or less never exhibited neurologic signs. The central nervous system (CNS) of affected dogs exhibited endothelial degeneration and hemorrhagic encephalopathy. Focal extravasation of horseradish peroxidase occurred frequently (6/8) in the retrolaminar optic nerve of asymptomatic or clinically affected dogs given 180 mg/kg/day lovastatin, with endothelial degeneration and discrete optic nerve degenerative lesions interpreted as ischemic. The association between the degree of hypocholesterolemia and occurrence of clinical signs was not exact. Total brain cholesterol was similar in treated and control dogs. Hypocholesterolemic dogs had proportionally lowered serum concentrations of alpha-tocopherol, but oral supplementation of this vitamin did not prevent the neurologic syndrome. Endothelial degeneration in the CNS and optic nerve may have reflected in vitro morphologic effects of HMG CoA reductase inhibitors due to extreme inhibition of nonsterol isoprene synthesis. Retinogeniculate axonal (Wallerian-like) degeneration occurred in greater than or equal to 12% of dogs given 60 mg/kg/day or more lovastatin, with central chromatolysis of occasional retinal ganglion cells. These neuroaxonal changes may have been secondary to vascular effects, but superimposed direct neurotoxic action at the high dosage levels of lovastatin could not be excluded. There was no evidence of drug induced adverse effects in the CNS of dogs given up to 30 mg/kg/day lovastatin for 2 years.

This article has been cited by other articles:

				T. N. Patel, M. H. Shishehbor, and D. L. Bhatt A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis Eur. Heart J., March 2, 2007; 28(6): 664 - 672. [Abstract] [Full Text] [PDF]

				S. D. Wiviott, C. P. Cannon, D. A. Morrow, K. K. Ray, M. A. Pfeffer, E. Braunwald, and for the PROVE IT-TIMI 22 Investigators Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 Substudy J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1411 - 1416. [Abstract] [Full Text] [PDF]

				D. G. Robertson, M. A. Breider, and M. A. Milad Preclinical Safety Evaluation of Avasimibe in Beagle Dogs: An ACAT Inhibitor with Minimal Adrenal Effects Toxicol. Sci., February 1, 2001; 59(2): 324 - 334. [Abstract] [Full Text] [PDF]

				K. M. Walsh and C. E. Rothwell Hepatic Effects in Beagle Dogs Administered Atorvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, for 2 Years Toxicol Pathol, July 1, 1999; 27(4): 395 - 401. [Abstract] [PDF]

				K. M. Walsh, M. A. Albassam, and D. E. Clarke Subchronic Toxicity of Atorvastatin, a Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, in Beagle Dogs Toxicol Pathol, July 1, 1996; 24(4): 468 - 476. [Abstract] [PDF]

				C. Iribarren, D. M. Reed, G. Wergowske, C. M. Burchfiel, and J. H. Dwyer Serum Cholesterol Level and Mortality Due to Suicide and Trauma in the Honolulu Heart Program Arch Intern Med, April 10, 1995; 155(7): 695 - 700. [Abstract] [PDF]

				K. Owen, C.R. Pick, S.E. Libretto, and M.J. Adams Toxicity of a Novel HMG-CoA Reductase Inhibitor in the Common Marmoset (Callithrix jacchus) Human and Experimental Toxicology, January 1, 1994; 13(5): 357 - 368. [Abstract] [PDF]